A Valuable Partner

Our unique approach to R&D goes beyond science and makes us an ideal partner for pharmaceutical companies and others working in the antiviral and liver disease areas. Being nimble, while maintaining focus allows us to work with a variety of partners to bring our research to where it will do the most good.

Today, we are working collaboratively with our partners; AbbVie (the former research-based pharmaceutical business of Abbott Laboratories), and the National Institutes of Allergy and Infectious Disease (NIAID), who share our goals of advancing our compounds as quickly as possible in order to treat a variety of serious infections.

Click here to learn more about our partnership opportunities.

abbvie logo

AbbVie (formerly Abbott Laboratories)

In December 2006, Enanta and Abbott announced a worldwide agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors and HCV protease inhibitor-containing drug combinations. Under the agreement, Abbott (now AbbVie) is responsible for and funds all costs associated with the development, manufacture and commercialization activities of paritaprevir, ABT-493 and any other compounds under this agreement. We received $57 million upon signing the collaboration agreement and Abbott’s simultaneous purchase of Enanta preferred stock and a total of $95 million of development milestone payments. We are eligible to receive additional regulatory approval milestones, as well as annually tiered, double-digit royalties  per product, based on annual net sales allocable to paritaprevir or to any of our collaborations’ additional HCV protease inhibitors.

Read the announcement


National Institutes of Allergy and Infectious Disease (NIAID)

In September 2011, we were awarded a contract from NIAID to fund preclinical and early clinical development of a new class of bridged bicyclic antibiotics known as Bicyclolides. Our lead candidate has been under development by NIAID as a medical countermeasures against multiple biodefense bacteria found in anthrax, plague and tularemia. In light of our strategic decision to discontinue commercial development of this antibiotic candidate for non-biodefense indications, which we communicated to NIAID in late 2014, we expect that our contract will be completed upon our delivery of the study report for our phase 1 study of the lead candidate, which is planned to be delivered in August 2015.